Role of Thrombin in Arterial Thrombosis: Implications for Therapy

• References

• 1 Fuster V, Badimon L, Cohen M, Ambrose JA, Badimon JJ, Chesebro JH. Insights into the pathogenesis of acute ischemic syndromes. Circulation 1988; 77: 1213-1220
• 2 Steele PM, Chesebro JH, Stanson AW, Holmes DR, Dewanjee M, Badimon L, Fuster V. Balloon angioplasty: A natural history of the pathophysiologic response to injury in a pig model. Circ Res 1985; 57: 105-112
• 3 Heras M, Chesebro JH, Penny WJ. et al Importance of adequate heparin dosage in arterial angioplasty in a porcine model. Circulation 1988; 78: 654-660
• 4 Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs: heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation 1989; 79: 657-665
• 5 Heras M, Chesebro JH, Webster MWI. et al. Hirudin, heparin, and placebo during deep arterial injury in the pig: The in vivo role of thrombin in platelet-mediated thrombosis. Circulation 1990; 82: 1476-1484
• 6 Lam JYT, Chesebro JH, Steele PM, Fuster V. Is vasospasm related to platelet deposition? in vivo relationship in a pig model of arterial injury. Circulation 1987; 75: 243-248
• 7 Fuster V, Stein B, Badimon L, Chesebro JH. Antithrombotic therapy after myocardial reperfusion in acute myocardiol infarction. J Am Coll Cardiol 1988; 12 (6) 78A-84A
• 8 Lam JYT, Chesebro JH, Fuster V. Platelets, vasoconstriction, and nitroglycerin during arterial wall injury: a new antithrombotic role for an old drug. Circulation 1988; 78: 712-716
• 9 Fischell TA, Derby G, Tse TM, Stadius ML. Coronary artery vasoconstriction routinely occurs after percutaneous transluminal coronary angioplasty: A quantitative arteriographic analysis. Circulation 1988; 78: 1323-1334
• 10 Heras M, Chesebro JH, Thompson PL, Fuster V. Prevention of early and late rethrombosis and further strategies after coronary reperfusion. In: Thrombolysis in Cardiovascualar Diseases. (Eds: Julian D, Kubler W, Norris Rm, Swan HJC, Collen D, Verstraete M. ) Marcel Dekker Inc, New York: 1989: 203-229
• 11 Califf RM, Topol EJ, George BS. Characteristics and outcome of patients in whom reperfusion with intravenous tissue-type plasminogen activator fails: Results of the Thrombolysis and Angioplasty in Myocardial Infaction (TAMI) I trial. Circulation 1988; 77: 1090-1099
• 12 Baim DS, Diver DJ, Knatterud GL. PTCA "salvage" for thrombolytic failures-implications from TIMI II-A. Circulation 1988; 78 (suppl II) II-112
• 13 Mabin TA, Holmes DR, Smith HC. et al. Intracoronary thrombus: role in coronary occlusion complicating percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1985; 5 (2) 198-202
• 14 Theroux P, Ouimet H, McCans J. et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105-1111
• 15 Badimon L, Lassila R, Badimon J, Vallabhajosula S, Chesebro JH, Fuster V. Residual thrombus is more thrombogenic than severely damaged vessel wall. Circulation 1988; 78 (Suppl II) II-119
• 16 Seegers WH, Nieft M, Loomis EC. Note of the absorption of thrombin on fibrin. Science 1945; 101: 520-521
• 17 Liu CY, Nossel HL, Kaplan KL. The binding of thrombin by fibrin. J Biol Chem 1979; 254: 10421-10425
• 18 Francis CW, Markham RE Jr., Barlow GH. Thrombin activity of fibrin thrombi and soluble plasmic derivatives. J Lab Clin Med 1983; 102: 220-230
• 19 Kaminski M, McDonagh J. Studies on the mechanism of thrombin: Interaction with fibrin. J Biol Chem 1983; 258: 10530-10535
• 20 Berliner LJ, Sugawara Y. Human -thrombin binding to nonpolymerized fibrin-sepharose: Evidence for an anionic binding region. Biochem 1985; 24: 7005-7009
• 21 Kaminski MMcDonagh. Inhibited thrombins: Interactions with fibrinogen and fibrin. Biochem J 1987; 242: 881-887
• 22 Vali Z, Scheraga HA. Localization of the binding site on fibrin for the secondary binding site of thrombin. Biochem 1988; 27: 1956-1963
• 23 Shuman MA. Thrombin-cellular interactions. Ann NY Acad Sci 1986; 485: 228-239
• 24 Mruk JS, Chesebro JH, Webster MWI. Platelet aggregation and interaction with the coagulation system: Implications for antithrombotic therapy in arterial thrombosis. J Corn Art Dis 1990; 1: 149-158
• 25 Fitzgerald DJ, Catella F, Roy L, Fitzgerald GA. Marked platelet activation in vivo after intravenous streptonkinase in patients with acute myocardial infarction. Circulation 1988; 7 7(1) 142-150
• 26 Eisenberg PR, Sherman L, Rich M. et al. Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. J Am Coll Cardiol 1986; 75: 1255-1262
• 27 Owen J, Friedman KD. Grossman: Thrombolytic therapy with tissue plasminogen activity. Blood 1988; 7 2(2) 616-620
• 28 Fitzgerald DJ, Wright F, Fitzgerald GA. Thrombin-mediated platelet activation during coronary thrombolysis. Circulation 1988; 78 (suppl II) II-120
• 29 Cercek B, Lew AS, Hod H. et al. Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin. Circulation 1986; 7 4(3) 583-587
• 30 Cercek B, Lew AS, Sato Y. et al. Haparin enhances experimental thrombolysis by preventing new fibrin deposition. Circulation 1985; 72 (Suppl III) III-194
• 31 Tomaru T, Uchida Y, Nakamura F. et al. Enhancement of arterial thrombolysis with native tissue type plasminogen activator by pretreatment with heparin or batroxobin: An angioscopic study. Am Heart J 1989; 117: 275-281
• 32 Golino P, Ashton JH, McNatt J. et al. Simultaneous administration of thromboxane A2-and serotonin S2-receptor antagonists remarkedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis. Circulation 1989; 79: 911-919
• 33 Jang IK, Gold H, Ziskind AA. et al. Differential sensitivity of erythrocyterich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator: A possible explanation for resistance to coronary thrombolysis. Circulation 1989; 79: 920-928
• 34 Fay WP, Owen WG. Platelet plasminogen activator inhibitor: purification and characterization of interaction with plasminogen activators and activated protein C inhibitor. Biochem 1989; 28: 5773-5778
• 35 Lam JYT, Chesebro JH, Badimon L, Fuster V. Serotonin and thromboxane A₂ receptor blockade decrease vasoconstriction but not platelet deposition after deep arterial injury. Circulation 1986; 74 (Suppl II) II-97
• 36 Markwardt F, Kaiser B, Novak G. Studies on antithrombotic effects of recombinant hirudin. Thromb Res 1989; 54: 377-388
• 37 Ambler J, Butler KD, Kerry R. et al. Comparative effects of selective thrombin inhibition by hirudin on coagulation and thrombosis. Circulation 1989; 80 (Suppl II) II-316 (Also personal communication with R.B. Wallis.)
• 38 Badimon L, Badimon JJ, Cohen M, Chesebro JH, Fuster V. Thrombosis formation in stenotic and laminar flow conditions: Effect on an antiplatelet GPIIb/IIIa monclonal antibody fragment [7E3F(ab'2]. Circulation 1989; 80 (Suppl II) II-422
• 39 Gold HK, Boston MA. personal communication
• 40 Badimon L, Badimon J, Lassila R, Heras M, Chesebro JH, Fuster V. Thrombin inhibition by hirudin decreases platelet thrombus growth on areas of severe wall injury. J Am Coll Cardiol 1989; 13: 145A
• 41 Mao SJ T, Yates MT, Owen TJ. et al. Interaction of hirudin with thrombin: Identification of a minimal binding domain of hirudin that inhibits clotting activity. Biochem 1988; 27: 8170-8173
• 42 Tam WS, Fenton JW, Detwiler TC. Dissociation of thrombin from platelets by hirudin. J Biol Chem 1979; 254: 8723-8725
• 43 Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin anti-thrombin III: Implications for heparin efficacy. Proc Natl Acad Sci USA 1989; 86: 3619-3623
• 44 Weitz JI, Hudoba M, Massel D, Maranganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptable to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-391
• 45 Massel DR, Hudoba M, Weitz JI. Clot-bound thrombin is protected from heparin inhibition-a potential mechanisms for rethrombosis after lytic therapy. Circulation 1989; 80 (Suppl II) II-420
• 46 Rentrop KP, Feit F, Blanke H. et al. Effects of intracoronary streptokinase and intracoronary nitroglycerin infusion on coronary angiographic patterns and mortality in patients with acute myocardial infarction. N Engl J Med 1984; 311: 1457-1463
• 47 Douglas Jr JS, Lutz JF, Clements SD. et al. Therapy of large intracoronary thrombi in candidates for percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1988; 11: 238A
• 48 Nakagawa S, Hanada Y, Koiwaya Y. et al. Angiographic features in the infarct-related artery after intracoronary urokinase follwed by prolonged anticoagulation. Role of ruptured atheromatous plaque and adherent thrombus in acute myocardial infarction in vivo. . Circulation 1988; 78: 1335-1344
• 49 Bar-Shavit R, Eldora A, Vlodavsky I. Binding of thrombin to subendothelial extracellular matrix: Protection and expression of functional properties. J Clin Invest 1989; 84: 1096-1104
• 50 Jaffe EA, Hoyer LW, Nachman RL. Synthesis of vonWillebrand Factor by cultured human endothelial cells. Proc Natl Acad Sci USA 1974; 71: 1906-1909
• 51 Knudson BS, Silverstein RL, Leung LLK, Harpel PC, Nachman RL. Binding of plasminogen to extracellular matrix. J Biol Chem 1986; 261: 10765-10771
• 52 Smith JC, Singh JP, Lillquist JS, Goon DS, Stiles CD. Growth factors adherent to cell substrate are mitogenically active in situ. Nature (Lond) 1982; 296: 154-156
• 53 Hatton MWC, Moar SL. A role for pericellular proteoclycan in the binding of thrombin or antithrombin III by the blood vessel endothelium. The effects of proteoglycan-degrading enzymes and glycosaminoglycan-binding proteins on ¹²⁵I-thrombin binding by rabbit thoracic aorta in vitro. . Thromb Haemostasis 1985; 53: 228-234
• 54 Hanson SR, Harker LA. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyly-arginyl chlormethyl ketone. Proc Natl Acad Sci USA 1988; 85: 3184-3188
• 55 Harker LA, Atlanta GA. personal communication
• 56 Williams EB, Krishnaswamy S, Mann KG. Zymogen/enzyme discrimination using peptide chlormethyl ketones. J Biol Chem 1989; 264: 7536-7545
• 57 Stone SR, Hofsteenge J. Kinetics of the inhibition of thrombin by hirudin. Biochem 1986; 25: 4622
• 58 Webster MWI, Chesebro JH, Heras M, Mruk JS, Grill DE, Fuster V. Short-term intravenous hirudin during balloon dilatation does not prevent platelet-thrombosis 48 hours after deep arterial injury. J Am Coll Cardiol 1991 (in press)
• 59 Jang I-K, Gold HK, Ziskind AA, Leinbach RC, Fallon JT, Collen D. Prevention of platelet-rich thrombosis by selective thrombin inhibition. Circulation 1990; 81: 219-225
• 60 Yasuda T, Gold HK, Yaoita H, Leinbach RC, Guerrero JL, Jang I-K, Hold R, Fallon JT, Collen D. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol 1990; 16: 714-722
• 61 Fitzgerald DJ, FitzGerald GA. Role of thrombin and thromboxane A₂ in reocclusion following coronary thrombolysis with tissue-type plasminogen activator. Proc Natl Acad Sci 1989; 86: 7885-9
• 62 Jang I-K, Gold HK, Leinbach RC, Fallon JT, Collen D. in vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator. Circ Res 1990; 67: 1552-1561
• 63 Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues: Implications for disorders of hemostasis and thrombosis. Am J Patjol 1989; 134: 1087-1097
• 64 Drake TA, Morrissey JH, Edgington TS. Immunohistochemical detection of tissue factor in human atherosclerotic plaques. Circulation 1989; 80 (Suppl II) II-182
• 65 Jang I-K, Gold HK, Leinbach RG, Fallon JT, Bunting S, Collen D, Wilcox JN. A monoclonal antibody against tissue factor prevents platelet-rich arterial thrombosis in the rabbit. J Am Coll Cardiol 1990; 15: 188A
• 66 Heras M, Chesebro JH, Webster MWI, Mruk JS, Grill DE, Badimon L, Fuster V. Antithrombotic efficacy of low molecular weight heparin after arterial injury in the pig. J Am Coll Cardiol 1990; 15: 188A
• 67 Meletich JP, Jackson CM, Majerus PW. Properties of the factor Xa binding site on human platelets. J Biol Chem 1978; 6908-6916
• 68 Teitel JM, Rosenberg RD. Protection of factor Xa from neutralization by the heparin-antithrombin complex. J Clin Invest 1983; 71: 1383-1391
• 69 Sturzebecher J, Sturzebecher U, Viewieg H, Wagner G, Hauptmann J, Markwardt F. Synthetic inhibitors of bovine factor Xa and thrombin: Comparison of their anticoagulant efficiency. Thromb Res 1989; 54: 245-252
• 70 Waxman L, Smith DE, Arcuri KE, Vlasuk GP. Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science 1990; 248: 593-596
• 71 Ip JH, Fuster V, Badimon L, Badimon J, Taubman MB, Chesebro JH. Syndromes of accelerated atherosclerosis: Role of vascular injury and smooth muscle cell proliferation. J Am Coll Cardiol 1990; 15: 1667-1687